DART partners GE Healthcare and Optellum announced that they have signed a letter of intent to collaborate to advance precision diagnosis and treatment of lung cancer. GE Healthcare is a global leader in medical imaging solutions. Optellum is the leader in AI decision support for the early diagnosis and optimal treatment of lung cancer.
A clinician’s AI-assisted diagnosis of malignancy may enable patients whose nodules are not malignant to avoid unnecessary and aggressive procedures such as biopsy and surgical resection, while expediting the diagnostic process, and enabling the right treatment to start earlier. This has the potential to provide patients with personalized diagnosis and treatment plans, enabling lung cancer patients to be treated at the earliest possible stage when survival rates are the highest. This is also the ambition of DART.
Read the full press release here.
Celebrate Doncaster LHC’s success
May 4, 2022
The Doncaster programme has been operational since mid-March 2021 and in the first year 11,857 lung health check calls and more…
Registration with ISRCTN
April 8, 2022
Optellum attains CE marking in Europe
April 5, 2022
Approvals and adoption
March 2, 2022